Floatz logo

Fycompa

WHO Grade 2 Glioma

Mayo ClinicPhase 4 / ApprovedDormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the WHO Grade 2 Glioma cohort.

Asset / SponsorPhaseRating
FET
Thomas Hope
Phase 2B
Pamiparib
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2B
ag-120
National Cancer Institute (NCI)
Phase 2CCC
Selpercatinib
National Cancer Institute (NCI)
Phase 2CCC
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 2CCC

View all 15 →

Same molecule, other indications

Fycompa is also rated in:

epilepsyDormant
BB
Indicative ·
71 / 100
View asset →
neuralgiaDormant
BB
Indicative ·
66 / 100
View asset →
epilepsyDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →